Gilead Sciences GILD Veklury — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gilead Sciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Gilead Sciences’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gilead Sciences's veklury — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gilead Sciences's veklury — total revenues?
- Gilead Sciences (GILD) reported veklury — total revenues of $144M in Q1 2026.
- How has Gilead Sciences's veklury — total revenues changed year-over-year?
- Gilead Sciences's veklury — total revenues decreased by 52.3% year-over-year, from $302M to $144M.
- What is the long-term trend for Gilead Sciences's veklury — total revenues?
- Over 4 years (2021 to 2025), Gilead Sciences's veklury — total revenues has grown at a -36.4% compound annual growth rate (CAGR), from $5.57B to $911M.
- What does veklury — total revenues mean?
- The total revenue generated from sales of the company's specific antiviral medication.
- How do you interpret veklury — total revenues?
- An increase indicates higher market adoption or demand for the therapy, while a decrease often reflects reduced clinical need or the impact of competitive alternatives in the infectious disease market.
- How does veklury — total revenues compare across companies?
- Similar to product-specific revenue metrics in other pharmaceutical companies, such as sales of individual blockbuster drugs or pandemic-related therapeutics, which are often sensitive to external health crises and seasonal demand.